James Wooldridge
Directeur Technique/Scientifique/R&D chez CHECKMATE PHARMACEUTICALS, INC.
Profil
James Wooldridge is currently the Chief Medical Officer at Checkmate Pharmaceuticals, Inc. He previously worked as the Chief Medical Officer at Spyre Therapeutics, Inc. from 2017 to 2019 and as the Chief Scientific Officer at Eli Lilly & Co. He received his doctorate degree from Tulane University in 1992 and his undergraduate degree from William Jewell College in 1988.
Postes actifs de James Wooldridge
| Sociétés | Poste | Début |
|---|---|---|
| CHECKMATE PHARMACEUTICALS, INC. | Directeur Technique/Scientifique/R&D | 01/10/2019 |
Anciens postes connus de James Wooldridge
| Sociétés | Poste | Fin |
|---|---|---|
| SPYRE THERAPEUTICS, INC. | Directeur Technique/Scientifique/R&D | 10/10/2019 |
| ELI LILLY AND COMPANY | Corporate Officer/Principal | - |
Formation de James Wooldridge
| William Jewell College | Undergraduate Degree |
| Tulane University (Louisiana) | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| SPYRE THERAPEUTICS, INC. | Health Technology |
| ELI LILLY AND COMPANY | Health Technology |
| Entreprise privées | 1 |
|---|---|
Checkmate Pharmaceuticals, Inc.
 Checkmate Pharmaceuticals, Inc. BiotechnologyHealth Technology Checkmate Pharmaceuticals, Inc. is a clinical-stage biotechnology company, which engages in developing and commercializing proprietary technology to harness the power of the immune system to combat cancer. The firm's product candidate, vidutolimod is a differentiated TLR9 agonist delivered as a biologic virus-like particle designed to trigger the body's innate immune system to attack tumors in combination with other therapies. The company was founded by Arthur M. Krieg and Chuck Yo in July 2015 and is headquartered in Cambridge, MA. | Health Technology |
